IBUPROFEN MUSCLE AND JOINT TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IBUPROFEN

Pieejams no:

PHARMASCIENCE INC

ATĶ kods:

M01AE01

SNN (starptautisko nepatentēto nosaukumu):

IBUPROFEN

Deva:

400MG

Zāļu forma:

TABLET

Kompozīcija:

IBUPROFEN 400MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

32/40/72/84

Receptes veids:

OTC

Ārstniecības joma:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108883002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2011-12-14

Produkta apraksts

PRODUCT MONOGRAPH
IBUPROFEN MUSCLE AND JOINT
Ibuprofen Tablets, USP
Caplets 400 mg
NON-STEROIDAL ANTI-INFLAMMATORY DRUG
ANALGESIC, ANTIPYRETIC AGENT.
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave, Suite #100
December 8, 2020
Montreal, Quebec, H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO.: 246393
_IBUPROFEN _
_MUSCLE AND JOINT-_
_ Product Monograph_
_ _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
................................................................................................13
DOSAGE AND ADMINISTRATION
...........................................................................16
OVERDOSAGE
...............................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY........................................................................................19
SPECIAL HANDLING INSTRUCTIONS
.......................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
................................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
CLINICAL TRIALS
...